Results from use of Cantargia’s antibodies against IL1RAP published in scientific journal Blood

An article by Cantargia AB’s (“Cantargia”) founder and Board member Dr Thoas
Fioretos and founder Dr Marcus Järås has been published in the respected
scientific journal Blood. In the article, Cantargia’s antibodies are utilized in
the treatment of chronic myeloid leukemia (CML) in preclinical models.
The article describes studies in preclinical models of chronic myeloid leukemia.
The results show a positive effect in these disease models from the use of
antibodies against IL1RAP. In particular, a clear treatment effect was evident
in “PDX” models, where tumour cells derived directly from patients are treated.
The researchers show that CAN04 hones in on the cancer cells and kills them by
attracting cells from the immune system. In the article they also show that the
interleukin-1 system plays a role in the growth of leukemia stem cells and that
CAN04 can curb the growth of these by blocking signals from IL1. The results
provide important information that can be of importance also for other forms of
cancer. Blood is a leading scientific journal published by the American Society
of Hematology (ASH).

“We are very pleased that a leading international journal like Blood has chosen
to publish data from studies with Cantargia’s antibodies”, Göran Forsberg, CEO
of Cantargia, says.

The article is available at www.bloodjournal.org.

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46 275 62 60
E-mail: goran.forsberg@cantargia.com
Certified Adviser: Sedermera Fondkommission

This constitutes information that Cantargia is required to publish under the
EU’s Market Abuse Regulation. The information was submitted for publication
through the above contact person on 13 September 2016, at 4 pm.